Find a Clinical Trial

Showing 51 - 60 of 169 Trials

A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05859334

Population:

Adult

Phase:

II

This study is being done to answer the following question: Will erdafitinib treatment be able to shrink or slow the growth of brain cancer that has returned or gotten worse after treatment? This study is being done to find out if treatment with erdafitinib is better or worse than the usual approach for your brain cancer. The usual approach is defined as care most people get for brain cancer: treatment with surgery, radiation, or FDA-approved drugs such as lomustine or bevacizumab. Sometimes, combinations of these treatments are used. Are you Eligible? (Inclusion Criteria) Are you 18 years of...
A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis (IMPACT-AL)

Principal Investigator:

Rajshekhar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT07110844

Population:

Adult

Phase:

II

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in Immunoglobulin Light Chain (AL) amyloidosis. Specifically, the study will look at whether this treatment can lower harmful proteins (light chains) in the blood that causes organ damage in AL amyloidosis. The goal is to stop further organ damage, facilitate organ recovery over the long run, and help patients live longer. Of note, daratumumab is currently Food and Drug Administration (FDA)-approved for the treatment of newly diagnosed AL amyloidosis. Teclistamab is not FDA-approved...
A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FORINTENSIVE CHEMOTHERAPY

Principal Investigator:

Sunil Girish Iyer, MD

Contact Number:

212-342-5162

NCT Number:

NCT06456463

Population:

Adult

Phase:

II

The purpose of this study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received study treatment for their acute myeloid leukemia (AML) before. The combination of Tag with Ven and Aza is experimental and this combination of all 3 drugs is not approved by the United States Food and Drug Administration (FDA) for the treatment for patients with AML. Are you Eligible? (Inclusion Criteria) Are you 18 years or older? -Are you able to give written informed consent and be able to comply with all study...
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating neoadjuvant therapy targeting the Adenosine immunosuppressive pathway in combination with Immune checkpoint blockade and Radiation Therapy in Patients with advanced PANCreatic Ductal

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06048484

Population:

Adult

Phase:

II

The main goal of this study is to find out if treatment with zimberelimab and stereotactic body radiation therapy alone or in combination with quemliclustat, with or without etrumadenant, given before surgery is safe and if it can further increase the immune response against the tumor. Are you Eligible? (Inclusion Criteria) You must have been diagnosed with advanced pancreatic adenocarcinoma. -You must be comfortable receiving study drug through a vein in your arm (intravenously). -You must be willing to undergo surgery.
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05968326

Population:

Adult

Phase:

II

The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus atezolizumab and mFOLFIRINOX compared with mFOLFIRINOX (standard of care chemotherapy) alone on patients with resected pancreatic ductal adenocarcinoma (PDAC). In this study, the participant will get either the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX or mFOLFIRINOX alone. Autogene cevumeran is a personalized drug product that will be made specifically for the participant and is designed to activate and train your immune system to find and kill cancer cells. Autogene...
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT05633615

Population:

Adult

Phase:

II

This study is being done to answer the following question: Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients who have a partial response or stable disease after CAR T-cell therapy is follow-up visits with no further therapy. Some patients will improve their response over time, but...
A pilot feasibility and efficacy (phase 2) trial of real time drug screening and genomic testing to determine an individualized treatment plan in children and young adults with relapsed medulloblastoma and ependymoma

Principal Investigator:

James H Garvin Jr, MD

Contact Number:

212-342-5162

NCT Number:

NCT05057702

Population:

Pediatrics/Adult

Phase:

II

The purpose of this single armed multi-center pilot trial is to allow every child and young adult with relapsed medulloblastoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign an individualized treatment...
A Phase II Trial of Tazemetostat Plus Mosunetuzumab In Untreated Follicular Lymphoma

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT05994235

Population:

Adult

Phase:

II

The purpose of this study is to test the efficacy of the combination of tazemetostat with mosunetuzumab and see what effects it has in your lymphoma. Tazemetostat is a drug that inhibits (reduces the ability of) EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system’s ability to fight it. Tazemetostat is Food and Drug Administration (FDA) approved in previously treated follicular lymphoma and currently undergoing study in other lymphomas. Mosunetuzumab is a bispecific...
A phase II single-arm study of cemiplimab, added to typical chemotherapy(gemcitabine, cisplatin, nab-paclitaxel) for down-staging of locally advanced, unresectablebiliary tract cancer

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

II

The purpose of this study is to combine chemotherapy that has previously been shown to have activity in patients with biliary tract cancer with a drug that stimulates the body’s immune system against cancer cells (immunotherapy). Previously, the combination of gemcitabine and cisplatin with immunotherapy has been shown to prolong life in patients with advanced biliary tract cancer. Adding nab-paclitaxel, another chemotherapy, to gemcitabine and cisplatin, has also been shown to prolong life in some patients with advanced biliary tract cancer. However, all four of these drugs have not...
A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma

Principal Investigator:

Andrew B. Lassman, MD, FAAN, FASCO

Contact Number:

212-342-5162

NCT Number:

NCT05303519

Population:

Adult

Phase:

II

The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have have life expectancy 3 months or more - Must have negative result for COVID

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages